WuXi Biologics (Cayman) Inc. Share Price OTC Markets

Equities

WXXWY

US98260N1081

Biotechnology & Medical Research

Delayed OTC Markets 19:38:32 28/05/2024 BST 5-day change 1st Jan Change
2.945 USD -6.80% Intraday chart for WuXi Biologics (Cayman) Inc. -11.69% -60.47%

Financials

Sales 2024 * 18.14B 2.5B 196B Sales 2025 * 21.59B 2.98B 233B Capitalization 45.28B 6.25B 489B
Net income 2024 * 3.85B 532M 41.63B Net income 2025 * 4.87B 672M 52.6B EV / Sales 2024 * 2.1 x
Net cash position 2024 * 7.25B 1B 78.35B Net cash position 2025 * 8.19B 1.13B 88.5B EV / Sales 2025 * 1.72 x
P/E ratio 2024 *
12.2 x
P/E ratio 2025 *
9.55 x
Employees 12,740
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.44%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.80%
1 week-11.69%
Current month-13.38%
1 month-16.47%
3 months-35.70%
6 months-74.61%
Current year-60.47%
More quotes
1 week
2.93
Extreme 2.925
3.33
1 month
2.93
Extreme 2.925
3.98
Current year
2.93
Extreme 2.925
7.87
1 year
2.93
Extreme 2.925
13.25
3 years
2.93
Extreme 2.925
38.00
5 years
2.93
Extreme 2.925
43.36
10 years
2.93
Extreme 2.925
43.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 31/05/11
Director of Finance/CFO 54 22/08/21
Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Director/Board Member 73 05/05/23
Director/Board Member 75 16/05/17
Chairman 56 30/04/10
More insiders
Date Price Change Volume
28/05/24 2.945 -6.80% 245 953
24/05/24 3.16 -0.88% 42,127
23/05/24 3.188 -3.74% 110,185
22/05/24 3.312 -0.69% 90,424
21/05/24 3.335 -4.71% 79,173

Delayed Quote OTC Markets, May 28, 2024 at 07:38 pm

More quotes
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
10.89 CNY
Average target price
25.19 CNY
Spread / Average Target
+131.26%
Consensus

Quarterly revenue - Rate of surprise